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Abstract
Introduction: Thyroid diseases, which may occur as focal or diffuse changes in thyroid parenchyma, are most often observed in women. 
Aim: Our aim was to assess the prevalence of incidental thyroid uptake of 68Ga-DOTATATE PET/CT in patients referred to the Nuclear 
Medicine Department for evaluation of neuroendocrine neoplasia (NEN). 
Material and methods: We retrospectively evaluated 1150 68Ga-DOTATATE PET/CT images. Clinical history, serum TSH and thyroid 
antibody (TAb) concentrations, ultrasonography, and cytological assessment of the material from fine-needle aspiration biopsy (FNA) of 
the thyroid lesion were investigated.
Results: We found incidental abnormalities in 46/1150 (4.1%) patients (12 men, 34 women). 34/46 patients (8 men, 26 women) showed 
diffuse 68Ga-DOTATATE thyroid uptake, with mean SUVmax 4.6 ± 1.6. Based on laboratory tests and ultrasound, we found: 38% of 
patients with an active autoimmune thyroiditis, 27% with benign goitre, and 6% with multinodular goitre with autoimmune thyroiditis. 
The remaining 29% of patients did not show any pathology. In 12/47 patients (4 men, 8 women) focal uptake in the thyroid with SUVmax 
7.3 ± 3.3 was found. During one-year follow-up, category II and category III lesions (according to Bethesda classification) were revealed 
in 9/12 (75%) patients and in one patient, respectively. Histopathological examination after surgery revealed papillary thyroid carcinoma 
in one patient and benign multinodular goitre in another patient. 
Conclusions: Patients with focal 68Ga-DOTATATE uptake should undergo further examination (FNA) due to potential risk of malignancy. 
Diffuse 68Ga-DOTATATE uptake was predominantly associated with active autoimmune thyroiditis or benign goitre. 
The focal lesions and diffuse pathology diseases were frequently seen in women. (Endokrynol Pol 2015; 66 (3): 231–236)
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Streszczenie
Wstęp: Zmiany w tarczycy mogą występować jako zmiany ogniskowe lub schorzenia dotyczące miąższu tarczycy, częściej stwierdzane są 
u kobiet. Celem pracy była ocena częstości występowania w badaniu 68Ga-DOTATATE PET/CT przypadkowo stwierdzonego wychwytu 
w tarczycy u pacjentów, kierowanych w celu oceny stopnia zaawansowania nowotworu neuroendokrynnego (NEN).
Materiał i metody: Analizie poddano 1150 badań 68Ga-DOTATATE PET/CT. Wynik badania PET/CT (ocena wizualna wychwytu, pomiar 
maksymalnego wychwytu znacznika SUVmax) analizowano wraz z historią kliniczną, stężeniem TSH w surowicy, poziomem przeciwciał 
przeciwtarczycowych (TAb), badaniem USG i oceną cytologiczną materiału z biopsji cienkoigłowej (BACC). 
Wyniki: Przypadkowe zmiany w tarczycy wykryto u 46/1150 (4,1%) pacjentów: 12 mężczyzn i 34 kobiet. U 34/46 pacjentów (8 mężczyzn, 
26 kobiet) stwierdzono rozlany wychwyt w tarczycy ze średnim SUVmax 4,6 ± 1,6. W tej grupie w badaniach laboratoryjnych i badaniu 
USG stwierdzono: u 38% aktywne autoimmunologiczne zapalenie tarczycy, u 27% wole obojętne, u 6% wole guzowate z komponentą 
autoimmunologiczną; u pozostałych 29% pacjentów nie stwierdzono żadnej patologii. U 12/46 pacjentów stwierdzono ogniskowy wy-
chwyt w tarczycy (4 mężczyzn, 8 kobiet) z SUVmax 7,3 ± 3,3 (zakres 3,9–12,6). U 9/12 w rocznych badaniach kontrolnych stwierdzono 
kategorię II, u jednego pacjenta kategorię III. W pooperacyjnym badaniu histopatologicznym stwierdzono raka brodawkowatego tarczycy 
u jednego pacjenta oraz u jednej osoby łagodny rozrost guzkowy. 
Wnioski: Ogniskowy wychwyt stwierdzony w badaniu 68Ga-DOTATATE PET/CT wymaga weryfikacji (BACC) ze względu na potencjalne 
ryzyko wystąpienia nowotworu złośliwego. Rozlany wychwyt 68Ga-DOTATATE PET/CT najczęściej wiąże się z aktywnym autoimmu-
nologicznym zapaleniem tarczycy i wolem guzkowym. Zarówno zmiany ogniskowe, jak i rozlany wychwyt w tarczycy występowały 
częściej u kobiet. (Endokrynol Pol 2015; 66 (3): 231–236)
Słowa kluczowe: receptory somatostatynowe, 68Ga-DOTATATE, PET/CT, wychwyt w tarczycy, nowotwory neuroendokrynne
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Introduction
Somatostatin receptors (SSTR1 to SSTR5) play an im-
portant role not only in the maintenance of normal 
thyroid physiology, but also in pathologic conditions. 
Somatostatin (SST) and SSTR1-5 are expressed in me-
dullary thyroid carcinoma (MTC) and differentiated 
thyroid cancers (DTC), but the role of SSTR subtypes is 
still not clear [1–3]. Some authors reported that SSTR2 
has been found to be the predominant subtype in 
DTC with a high expression particularly in papillary 
cancer [4]. SSTR2 also seems to play an important role 
in the pathophysiology of benign thyroid diseases [5]. 
Recently published studies suggest that SSTR2 was the 
most common receptor expressed in benign diseases 
like multinodular goitre, Graves’ disease, Hashimoto 
disease, or follicular adenoma [6]. 
On the other hand, 68Ga labelled somatostatin (SST) 
analogues (like: DOTATATE and DOTATOC) have high 
affinity to SSTR2. Significant correlation was found 
between SSTR2 expression and the maximum Stand-
ardised Uptake Value (SUVmax) as a semiquantitative 
parameter on the PET/CT [7]. The visualisation of SSTR2 
status in vivo with radiolabelled SST analogues help to 
define the role of SSTR2 in thyroid diseases. 
The incidental 68Ga-DOTATATE or 68Ga-DOTATOC 
uptake seen in the thyroid gland is not an occasional 
finding on diagnostic PET/CT scans during diagnosis 
of neuroendocrine neoplasia (NEN). In the published 
data the problem of unexpected increased uptake of 
68Ga-labelled SST analogues in thyroid gland and clini-
cal significance of such findings has not been presented 
yet and needs further evaluation. 
The aim of the study was to evaluate the prevalence 
of incidental thyroid uptake of 68Ga-DOTATATE PET/CT 
in patients referred to the Nuclear Medicine Depart-
ment for evaluation of NEN. 
Material and methods
The study was approved by the Ethical Committee of 
the Medical University of Warsaw. Written informed 
consent was obtained from all patients.
We retrospectively evaluated 1150 patients with 
NEN, who underwent 68Ga-DOTATATE PET/CT imag-
ing between January 2010 and March 2013. 
Clinical history, serum TSH levels, thyroid anti-
bodies (TAb), ultrasonography, and cytological as-
sessment of the material from fine-needle aspiration 
biopsy (FNA) of the thyroid lesion were investigated. 
The cytology exa mination was described by Bethesda 
classification [8].
Laboratory examination: serum thyroid-stimu-
lating hormone (TSH), free thyroxine (fT4), free trii-
odothyronine (fT3), serum thyroperoxidase antibody 
(ATPO), and thyroglobulin antibody (ATG) were 
measured using the chemiluminescence method (Im-
mulite 1000 Siemens Healthcare Diagnostics, Architect 
ci 8200 Abott).
The normal range for TSH level was defined as 
0.4–4.0 µIU/mL, for fT4 0.89–1.76 ng/dL, for fT3 1.5– 
–4.1 pg/mL, ATPO < 35.0 IU/mL, and ATG < 115.0 IU/mL.
68Ga -DOTATATE PET/CT scans were performed not 
earlier than five weeks after the last injection of long-
acting SST analogues — octreotide and seven weeks 
after lanreotide. 
Sites of thyroid pathological uptake were noted and 
confirmed on ultrasound (US) (Voluson E8, linear probe 
6 cm/1,0/25Hz) and FNA. 
PET/CT imaging
Preparation of radiopharmaceutical 68Ga –DOTATATE 
and the 68Ga -DOTATATE PET/CT was performed using 
a previously-described procedure [9].
Image analysis
Image analysis was performed using a Multi-Modality 
Work Station (MMWS), Syngo (TrueD) (Siemens Medi-
cal Solutions). Attenuation-corrected PET images and 
PET/CT images were analysed. The PET images without 
attenuation correction were also reviewed. The PET/CT 
fusion images were used for evaluation of uptake using 
volume regions of interest (ROIs). The SUV maximum 
and mean were calculated in all ROIs using the follow-
ing formula:
SUVmax = Maximum Activity Concentration at time 
from pixel values/(Injected Dose/Patient Weight)
The thyroid uptake of 68Ga-DOTATATE was ana-
lysed: firstly qualitative-visual analysis of distribution 
pattern and semiquantitative with measurement of 
SUVmax.
Statistical methods 
Patient characteristics, thyroid SUVmax, TAb level, and 
serum TSH were characterised by the mean (± SD) 
and median .
To assess the normal distribution data we used the 
Shapiro-Wilk test and graphical analysis by inspection 
of the histograms. Spearman’s correlation coefficient 
was used to determine the association of thyroid 
SUVmax with ATPO and TSH. The tests were two-sided 
and a p-value of < 0.05 was considered statistically 
significant.
Calculations were performed using Statistica soft-
ware (6.0 Stat Soft, Inc. 1984–2002) and Excel (Microsoft 
Office Professional Edition 2013).
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Results
Labelling and imaging procedure
68Ga-DOTATATE was successfully labelled with a radio-
chemical purity of over 99%. For PET/CT examination 
a mean injected activity of 68Ga-DOTATATE of 156.4 
± 18.1 MBq, (range: 120–200 MBq) was administered 
without any major side effects. 
Thyroid uptake
Among 1150 patients with histological confirmation of 
NEN (G1 — 42% and G2 — 58%), referred for staging 
or restaging after surgery, we revealed abnormalities 
in the thyroid in 46 (4.1%) patients (12 males and 34 
females, mean age 63.8 years ± 10.8; range 25–85 years) 
with the prevalence significantly higher in women 3.0% 
than in men 1.1%. 
The incidental increased uptake of 68Ga-DOTATATE 
in the thyroid gland was defined as focal or diffuse, 
inhomogeneous. A diffuse uptake was noted in 74% 
of patients and focal in 26% of patients. 
Subsequently we analysed the clinical significance of 
abnormal radiotracer distribution pattern in the thyroid 
gland and the impact of such a finding on the clinical 
management of those patients. We compared it with 
ultrasound, TSH level, TAb, and FNA.
Thyroid diffuse uptake
Increased diffuse, inhomogeneous 68Ga-DOTATATE 
thyroid uptake was seen in 34/46 patients (8 males, 26 
females, mean age 49.5 years ± 16.7; range 25–85). Labo-
ratory tests and ultrasonography revealed: Hashimoto 
disease in 13 patients (38.2%), multinodular goitre in 
9 patients (26.6%), and multinodular goitre coexisting 
with Hashimoto disease in 2 patients (5.8%) (Figs. 1 and 2). 
In the remaining 10 patients (29.4%) no abnormalities 
of laboratory tests and ultrasound were seen. 
The mean SUVmax was 4.6 ± 1.6, and median 
SUVmax was 5.3 (range 2.0–10.9). 
The mean TSH level was 1.8 ± 1.2 mIU/L and me-
dian 1.7 mIU/L (range: 0.005–5.3 mIU/L). In patients 
with Hashimoto disease the mean ATPO level was 
327.0 ± 733.3 IU/mL, median 67.5 IU/ ml (range: 17.3––
2821 IU/mL), the mean ATG level was 99.6 ± 84.0 IU/mL, 
and median 65.0 IU/mL (range: 19.2–282.0 IU/mL).
Before 68Ga-DOTATATE PET/CT imaging 15/34 
(44%) patients had no prior history of thyroid disease. 
Among them, laboratory test and ultrasound revealed 
Hashimoto disease in 5 patients, and the remaining 10 
patients did not reveal pathology within 6–12-month 
follow-up.
19/34 (66%) patients had previous history of thyroid 
disease; 10 patients had long-term supplementation 
with L-thyroxine, 2 patients Thiamazole therapy.
Spearman correlation coefficient showed no corre-
lation between thyroid SUVmax value and the ATPO 
level (rho = –0.107, p = 0.547) and SUVmax and TSH 
value (rho = 0.017, p = 0.924).
Focal thyroid uptake
12/46 patients (4 males, 8 females, mean age 55.5 ± 17.2 
years, range 35–78) had focal uptake in the thyroid. 
All patients had prior history of thyroid diseases: one 
patient had Hashimoto disease, six patients had multi-
nodular goitre coexisting with Hahimoto disease, and 
five patients had multinodular goitre. Among them 
three patients were receiving substitutive therapy 
with L-thyroxine and one patient with multinodular 
goitre Thiamazole therapy. The ultrasound revealed 
hypoechogenic lesions in 10 patients and irregular 
echogenicity in 2 patients.
The mean thyroid SUVmax was 7.3 ± 3.1, and me-
dian SUVmax 6.6 (range 2.8–12.6). The mean TSH level 
was 3.0 ± 4.9 mIU/L, and the median was 1.47 mIU/L 
(range 0.06–19.2 mIU/L).
Based on histopathology 2/12 patients after thy-
roidectomy revealed the following: one patient had 
papillary thyroid cancer (SUVmax 11.6) (Fig. 3), and 
one patient had benign multinodular goitre. Among 
the remaining 9/12 patients managed with a 12-month 
follow-up all had category II lesion (Fig. 4). One pa-
tient’s (with category III lesion) follow-up data was 
unavailable. 
Discussion
The spread of 68Ga-DOTA-somatostatin analogues 
PET/CT availability as a new standard imaging for the 
diagnosis of patients with NEN forces us to clarify the 
clinical role of incidental radiotracer uptake seen in the 
thyroid gland. In addition, no guidelines have been 
drawn up for the clinical assessment and management 
of such abnormalities.
In visual analysis normal 68Ga-DOTATATE uptake 
tends to be bilateral, diffuse, homogenous, and only 
slightly visible on maximum intensity projection (MIP), 
with mean SUVmax 2.9 ( ± 1.2) [9]. Knowledge of nor-
mal 68Ga-DOTATATE distribution in the thyroid gland is 
crucial for accurate image interpretation, which should 
not be confused with any pathology. The assessment of 
the functional SSTR2 receptor status in vivo in normal 
thyroid by 68Ga-DOTATATE PET/CT seems to be par-
tially consistent with the results obtained in vitro, but 
published studies are still very limited and often con-
troversial [3, 5, 6, 10]. In the normal thyroid, increased 
expression of SSTR3 and SSTR5 have been documented 
by molecular methods, whilst SSTR2 expression was at 
very low levels [1]. In immunochemistry (IHC) some 
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Figure 1. PET/CT with 68Ga-DOTATATE in patients with pancreatic NEN G2 with diffuse, homogenous uptake in thyroid gland 
(SUVmax 9.8). US as well, laboratory tests revealed Hashimoto disease (Fusion PET/CT, PET, CT)
Rycina 1. Badanie 68Ga-DOTATATE PET/CT u pacjenta z NEN G2 trzustki, z widocznym rozlanym, jednorodnym gromadzeniem 
znacznika w gruczole tarczowym (SUVmax 9.8). W badaniu USG oraz w badaniach laboratoryjnych potwierdzono chorobę Hashimoto 
(Fuzja PET/CT, PET, CT)
Figure 2. PET/CT with 68Ga-DOTATATE in patients with ileal NEN G1 with diffuse, nonhomogeneous uptake (SUVmax 3.3). US as 
well, laboratory test revealed Hashimoto disease (Fusion PET/CT, PET, CT)
Rycina 2. Badanie 68Ga-DOTATATE PET/CT u pacjenta z NEN G1 jelita cienkiego, z widocznym rozlanym, niejednorodnym 
gromadzeniem znacznika w gruczole tarczowym (SUVmax 3.3). W badaniu USG oraz w badaniach laboratoryjnych potwierdzono 
chorobę Hashimoto (Fuzja PET/CT, PET, CT)
Figure 3. PET/CT with 68Ga-DOTATATE in patients with gastric NEN G1 with focal uptake in the right lobe (SUVmax 11.6). FNA 
biopsy as well as post-surgical examination revealed papillary carcinoma (Fusion PET/CT, PET, CT)
Rycina 3. Badanie 68Ga-DOTATATE PET/CT u pacjenta z NEN G1 żołądka, z widocznym ogniskiem gromadzenia znacznika w prawym 
płacie tarczycy (SUVmax 11.6). W biopsji cienkoigłowej oraz w pooperacyjnym badaniu histopatologicznym – rak brodawkowaty 
tarczycy. (Fuzja PET/CT, PET, CT)
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authors found that in the normal thyroid tissue SSTR2 
was expressed in 13%, SSTR3 in 24%, and SSTR5 only 
in 2%, without expression of SSTR1or SSTR4 [10]. 
Conversely, in a recently published study SSTR expres-
sion was highly expressed in normal thyroid tissue for 
SSTR1, SSTR3, SSTR4, and SSTR5, whilst SSTR 2a was 
not expressed at all [6]. Results depend on the investiga-
tion method used - expression of receptors at the level 
of mRNA SSTRs or IHC [1, 6, 10–12]. 
A study of the Polish population revealed thyroid 
dysfunctions in over 10% of older patients, but 80% of 
them were subclinical [13]. In our study an unexpected 
increase of 68Ga-DOTATATE uptake in the thyroid gland 
was seen in 4.1% of patients.
Most of them presented a diffuse pattern as predo-
minantly seen in Hashimoto disease and less frequently 
in multinodular goitre and normal thyroid gland. Data 
in the literature regarding SSTR2 expression in vivo in 
benign thyroid pathologies are still limited with a very 
small sample size [14–20]. 
In patients with NEN, who underwent 111In-octreo-
tide scintigraphy for tumour localisation, the increased 
uptake of radiotracer was seen predominantly in en-
demic goitre with or without thyroid autonomy [14]. 
The diffuse, bilateral uptake of 111In-octreotide or 111In-
pentetreotide as a dominant pattern in patients with 
autoimmune thyroiditis (AITD): Graves’ disease and 
Hashimoto disease [15–18], was reported by other 
authors. Thyroid 111In-pentetreotide accumulation in 
Graves’ disease patients was increased seven fold com-
pared to the control group and was almost absent after 
radioiodine-induced hypothyroidism [15]. In untreated 
hyperthyroid patients a positive correlation between 
111In-pentetreotide uptake in the thyroid and TSH, fT4, 
fT3, as well receptor autoantibodies levels was found. 
These correlations were absent after treatment with 
Thiamazole [17].
Currently, because of its higher sensitivity, PET/ 
/CT with 68Ga-labelled somatostatin analogues is the 
preferred diagnostic method for detection of SSTR2 in 
vivo [24]. The majority of published studies focus on 
the clinical value 68Ga-labelled somatostatin analogues 
PET/CT in patients with non-radioiodine-avid DTC and 
high thyroglobulin levels [21–23]. 
The both studies suggest that increased 68Ga-labelled 
SST analogues uptake in thyroid in patients with AITD 
might be related to the activity of autoimmune diseases 
[18, 19]. Both studies suggest that increased 68Ga-la-
belled SST analogues uptake in thyroid in patients with 
AITD might be related to the activity of autoimmune 
disease. Intense tracer uptake was found in some cases 
(4.8%) of structurally and functionally normal thyroid 
lobes, but follow-up after 6–14 months did not show 
any thyroid pathology [20].
Normal thyroids as well as ones with non-toxic nod-
ules and goitres showed a clearly detectable radiotracer 
uptake with large variability [19]. The radiotracer 
uptake seen in thyroid can reflect a dense infiltration 
of lymphocytes that express SSTR2 on their plasma 
membrane [16, 17, 19, 20]. 
Contrary to published studies, we found the diffuse 
pattern with nearly the same frequency for multinodu-
lar goitre as for normal thyroid gland. In our series 
about 30% of patients with increased, inhomogeneous 
68Ga-DOTATATE uptake had normal thyroid gland, 
and 12-month follow-up did not reveal any pathology. 
Longer follow-up studies are needed to determine 
whether increased 68Ga-DOTATATE uptake in these 
Figure 4. PET/CT with 68Ga-DOTATATE in patients with unknown primary NEN with focal uptake in the right lobe (SUVmax 4.2). 
US and FNA biopsy examination revealed category II lesion in multinodular goitre (Fusion PET/CT, PET, CT)
Rycina 4. Badanie 68Ga-DOTATATE PET/CT u pacjenta z NEN o nieznanym punkcie wyjścia z widocznym ogniskiem gromadzenia 
znacznika w prawym płacie tarczycy (SUVmax 4.2). W badaniu USG oraz biopsji cienkoigłowej- zmiana kategorii II w wolu 
wieloguzkowym (Fuzja PET/CT, PET, CT)
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patients can predict future autoimmune thyroiditis or 
demonstrate normal distribution pattern. 
A fundamental problem is differential diagnosis 
between malignant and benign lesions in focal 68Ga-
DOTATATE uptake in thyroid gland, which was noted 
in 26% of patients. 
The prevalence of malignancy among this group 
was 8% (papillary thyroid cancer). Subsequent biopsy 
recommended after 68Ga-DOTATATE PET/CT critically 
changed in the management of this patients. Interest-
ingly, in published studies the focal pattern was asso-
ciated mainly with hot thyroid nodule (in 99mTc) and less 
frequently with benign cold nodules [19, 20]. Due to the 
high expression of SSTR2 reported in papillary thyroid 
cancer and benign thyroid nodules in vitro and in vivo 
studies is probable that the high value of SUVmax could 
be seen in both conditions [5, 6, 19, 20]. Therefore, in 
the case of focal uptake of 68Ga-DOTATATE, the patient 
should undergo further examination, including ultra-
sonography and FNA, to exclude a thyroid carcinoma. 
Our study, for the first time, underlined the clinical 
significance of an unexpected increase in 68Ga-DOTA-
TATE uptake in the thyroid gland seen on PET/CT. One 
of the main limitations of this study is its retrospective 
design, which may have introduced potential selection 
bias. For some of the variables the follow-up data were 
scarce. Another important limitation is that the study 
population included a small percentage with inciden-
tal, abnormal thyroid uptake seen in all performed 
examinations. In particular, due to the small number of 
patients, the methods of statistical analysis used were 
limited. For all of the above-mentioned reasons the 
results should be interpreted with appropriate caution. 
Conclusions
Patients with focal 68Ga -DOTATATE uptake should 
undergo further examination due to potential risk 
of malignancy. Diffuse 68Ga-DOTATATE uptake was 
predominantly associated with active autoimmune 
thyroiditis or benign goitre. 
Both focal and diffuse thyroid pathologies were 
often seen in women.
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